Current Report Filing (8-k)

Date : 06/19/2019 @ 1:06PM
Source : Edgar (US Regulatory)
Stock : Momenta Pharmaceuticals Inc (MNTA)
Quote : 14.34  -0.03 (-0.21%) @ 4:23PM

Current Report Filing (8-k)

 

 

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

 

FORM 8-K

 

CURRENT REPORT

Pursuant to Section 13 or 15(d) of
The Securities Exchange Act of 1934

 

Date of Report (Date of earliest event reported): June 19 , 2019

 

Momenta Pharmaceuticals, Inc.

(Exact name of registrant as specified in its charter)

 

Delaware

 

000-50797

 

04-3561634

(State or Other Jurisdiction

 

(Commission

 

(IRS Employer

of Incorporation)

 

File Number)

 

Identification No.)

 

301 Binney Street, Cambridge, MA

 

02142

(Address of Principal Executive Offices)

 

(Zip Code)

 

(617) 491-9700

(Registrant’s telephone number, including area code)

 

Not applicable

(Former name or former address, if changed since last report)

 

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):

 

o                                     Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

 

o                                     Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

 

o                                     Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

 

o                                     Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

 

Securities registered pursuant to Section 12(b) of the Act:

 

Title of each class

 

Trading Symbol(s)

 

Name of each exchange on which
registered

Common Stock, $0.0001 par value per share

 

MNTA

 

The Nasdaq Global Select Market

 

Indicate by check mark whether the registrant is an emerging growth company as defined in as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

 

Emerging growth company o

 

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.    o

 

 

 


 

Item 8.01. Other Events.

 

On June 19, 2019, Momenta Pharmaceuticals, Inc. (“Momenta”), together with Sandoz Inc. (“Sandoz”), announced that they have entered into a settlement agreement (the “Agreement”) with Amphastar Pharmaceuticals, Inc. and International Medication Systems, Ltd. (Amphastar Pharmaceuticals, Inc. and International Medication Systems, Ltd. individually and collectively referred to as “Amphastar”) to settle certain patent infringement litigation relating to a Momenta patent for its generic enoxaparin product (the “Patent Action”) and related antitrust litigation (the “Antitrust Action,” and collectively with the Patent Action, the “Actions”) between the parties.

 

The United States District Court for the District of Massachusetts had entered final judgment in the Patent Action in March 2018, finding that Amphastar infringed Momenta’s patent, but that the patent was invalid and unenforceable against one of the two infringing methods used by Amphastar (the “Patent Judgment”). The Agreement became effective on June 18, 2019, upon the United States District Court for the District of Massachusetts’ entry of a final order of vacatur (the “Vacatur Order”) of the Patent Judgment. Momenta will pay $21 million to Amphastar by July 2, 2019 under the terms of the Agreement.

 

As previously disclosed, Momenta had posted $36.1 million as collateral for a $100 million security bond required to be posted by Momenta and Sandoz in connection with the Patent Action, and had classified the collateral as restricted cash in its consolidated balance sheet.

 

2


 

SIGNATURES

 

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

 

 

MOMENTA PHARMACEUTICALS, INC.

 

 

Date: June 19, 2019

By:

/s/ Craig A. Wheeler

 

 

Craig A. Wheeler

 

 

President and Chief Executive Officer

 

3


Momenta Pharmaceuticals (NASDAQ:MNTA)
Historical Stock Chart

1 Year : From Oct 2018 to Oct 2019

Click Here for more Momenta Pharmaceuticals Charts.

Momenta Pharmaceuticals (NASDAQ:MNTA)
Intraday Stock Chart

Today : Tuesday 22 October 2019

Click Here for more Momenta Pharmaceuticals Charts.

Latest MNTA Messages

{{bbMessage.M_Alias}} {{bbMessage.MSG_Date}} {{bbMessage.HowLongAgo}} {{bbMessage.MSG_ID}} {{bbMessage.MSG_Subject}}

Loading Messages....


No posts yet, be the first! No {{symbol}} Message Board. Create One! See More Posts on {{symbol}} Message Board See More Message Board Posts


Your Recent History
LSE
GKP
Gulf Keyst..
LSE
QPP
Quindell
FTSE
UKX
FTSE 100
LSE
IOF
Iofina
FX
GBPUSD
UK Sterlin..
Stocks you've viewed will appear in this box, letting you easily return to quotes you've seen previously.

Register now to create your own custom streaming stock watchlist.


NYSE, AMEX, and ASX quotes are delayed by at least 20 minutes.
All other quotes are delayed by at least 15 minutes unless otherwise stated.